BIOATLA INC (BCAB) Stock Analyst Ratings
NASDAQ:BCAB • US09077B1044
0.15 USD
-0.01 (-8.93%)
At close: Feb 13, 2026
0.1502 USD
+0 (+0.13%)
After Hours: 2/13/2026, 8:00:01 PM
ChartMill assigns a Buy % Consensus number of 86% to BCAB. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 10.2. This target is 6700% above the current price.
- BCAB was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about BCAB.
- In the previous month the buy percentage consensus was at a similar level.
- BCAB was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-13 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-03-31 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-05-23 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-05 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-02 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-08-02 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | JMP Securities | Reiterate | Outperform -> Outperform |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-04-17 | EF Hutton | Maintains | Buy |
| 2023-04-03 | JP Morgan | Maintains | Overweight |
| 2023-03-28 | BTIG | Maintains | Buy |
| 2023-03-27 | JMP Securities | Maintains | Outperform |
| 2023-03-24 | EF Hutton | Reiterate | Buy |
| 2023-03-24 | Credit Suisse | Reiterate | Neutral |
| 2023-03-24 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-05 | EF Hutton | Initiate | Buy |
| 2022-11-04 | Credit Suisse | Maintains | Neutral |
| 2022-09-15 | JMP Securities | Initiate | Market Outperform |
BIOATLA INC / BCAB FAQ
What is the average price target for BIOATLA INC (BCAB) stock?
7 analysts have analysed BCAB and the average price target is 10.2 USD. This implies a price increase of 6700% is expected in the next year compared to the current price of 0.15.
What is the consensus rating for BCAB stock?
The consensus rating for BIOATLA INC (BCAB) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed BIOATLA INC (BCAB)?
The number of analysts covering BIOATLA INC (BCAB) is 7.